Lubiprostone

Drug Profile

Lubiprostone

Alternative Names: Amitiza; RU-0211; SPI-0211

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sucampo Pharmaceuticals
  • Developer Sucampo Pharmaceuticals; Takeda
  • Class Gastrokinetics; Irritable bowel syndrome therapies; Laxatives; Monounsaturated fatty acids; Prostaglandins; Small molecules
  • Mechanism of Action Chloride channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation; Irritable bowel syndrome
  • Discontinued Postoperative ileus

Most Recent Events

  • 03 Oct 2017 Sucampo does not intend to move forward with its sNDA submission for Constipation (In adults) [PO, Sprinkle (Granules)]
  • 01 Oct 2017 Sucampo Pharmaceuticals completes a phase III trial for chronic idiopathic Constipation in Japan (PO, Capsule) (JapicCTI163442)
  • 28 Sep 2017 Preregistration for Constipation (In adolescents, In children) in USA (PO, Capsule) before September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top